Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 37 of the 55 sources its claims cite were checked for support.
Abstract
mice, were largely maintained during spaceflight. Systemic inhibition of MSTN/activin A signaling using a soluble form of the activin type IIB receptor (ACVR2B), which can bind each of these ligands, led to dramatic increases in both muscle and bone mass, with effects being comparable in ground and flight mice. Exposure to microgravity and treatment with the soluble receptor each led to alterations in numerous signaling pathways, which were reflected in changes in levels of key signaling components in the blood as well as their RNA expression levels in muscle and bone. These findings have implications for therapeutic strategies to combat the concomitant muscle and bone loss occurring in people afflicted with disuse atrophy on Earth as well as in astronauts in space, especially during prolonged missions.
Overview
CoChat Summary
## TL;DR
This mouse ISS study tested whether blocking myostatin/activin A signaling with ACVR2B/Fc or genetic Mstn deletion could protect against microgravity-induced muscle and bone loss. The paper reports that ACVR2B/Fc significantly increased lean mass and bone measures in flight mice and helped restore both muscle and bone after return to Earth.
## Key findings
- Muscle loss from spaceflight: In wild type mice exposed to microgravity for 33 days, lean body mass was 9% lower, and weights of the pectoralis, triceps, quadriceps, gastrocnemius/plantaris, and soleus were 8%, 8%, 15%, 14%, and 18% lower, respectively, than ground controls.
- ACVR2B/Fc improved muscle growth in flight: In flight mice, lean body mass increased by 27% over 22 days after ACVR2B/Fc treatment, compared with 18% in ground mice over the same interval; individual muscle weights at return were significantly higher than in uninjected flight mice.
- Bone loss from spaceflight and protection by ACVR2B/Fc: In uninjected flight mice, whole-body, left femur, and right femur BMD fell by 8%, 11%, and 8% over 22 days in microgravity. ACVR2B/Fc increased BMD in ground mice by 4%, 10%, and 9% and brought BMD in flight mice to levels comparable to uninjected ground mice.
- MicroCT showed strong skeletal protection: In femurs of uninjected flight mice, BV/TV, trabecular thickness, trabecular number, and cortical thickness were reduced by 37%, 8%, 9%, and 9%; ACVR2B/Fc increased these in ground mice by 96%, 10%, 31%, and 12%, and in flight mice the femoral BV/TV and trabecular number were described as nearly indistinguishable from ACVR2B/Fc-treated ground mice.
- Recovery after return to Earth: After 2 weeks on Earth, untreated mice recovered muscle mass to baseline, but ACVR2B/Fc further increased muscle weights to 39%, 36%, 34%, 26%, and 20% above baseline for pectoralis, triceps, quadriceps, gastrocnemius/plantaris, and soleus, respectively; bone mass also showed conservation or gain with treatment.
## Methods
- Design and sample: The study sent 40 female mice to the ISS in five groups of eight: untreated wild type, ACVR2B/Fc-treated wild type, and Mstn−/− mice, plus additional wild type groups kept on Earth for postflight recovery; there were also 24 ground control mice matched to flight conditions.
- Intervention and timing: ACVR2B/Fc was administered intraperitoneally at 175 μg per injection on scheduled days before/during/after flight; mice were analyzed either at live animal return or after 14 days of recovery on Earth.
- Main analyses: The paper used DXA, microCT, RNAseq, SomaScan proteomics, and ELISA to assess muscle, bone, and pathway changes.
## Limitations
- The authors state that additional studies will be required to understand the basis of the unexpected higher humerus BMD seen early in flight, so that result remains unexplained in the paper.
- They state they did not measure body water content, so the apparent rapid postflight muscle recovery could partly reflect water shifts rather than true tissue recovery.
- Evidence evident from the text: the study used female mice only, so direct generalization to males is not supported by the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
27 Valid · 1 Not valid · 4 Not checked · 73 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Because TRAIL and RANKL are known to regulate osteoclast differentiation and survival (33–35), these findings suggest that increased RANK (tumor necrosis factor receptor superfamily member 11a) signaling may be involved in the regulation of bone growth and remodeling induced by ACVR2B/Fc.”
§ Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight > Results and Discussion
What the sources say
- Not checked — no full text of the sourcecites [33] Boyle W. J., Simonet W. S., Lacey D. L., Osteoclast differentiation and activation. Nature 423, 337– 342 (2003). 12748652 source
- Not checked — no full text of the sourcecites [34] Zauli G.., TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors. J. Cell. Physiol. 214, 117– 125 (2008). 17620297 source
- Partly supportedcites [35] Baud’huin M.., Osteoprotegerin: Multiple partners for multiple functions. Cytokine Growth Factor Rev. 24, 401– 409 (2013). 23827649 sourceExperimental — accuracy not yet measured
The citation is attached to the premise about osteoclast differentiation and survival; the ACVR2B/Fc mechanism is the citing authors’ own inference. In “RANKL and TRAIL: ligands from the TNF family” (page unavailable), the source says RANKL–RANK signaling regulates osteoclast differentiation and survival, but it does not establish the same role for TRAIL. (LLM, conf=0.84)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“We showed previously that treatment with ACVR2B/Fc can induce rapid muscle growth (13), and indeed, the decoy receptor increased lean body mass in ground mice by 11% in just 12 d (Fig. 1D).”
§ Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight > Results and Discussion
What the sources say
- Supportedcites [13] Lee S.-J.., Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. U.S.A. 102, 18117– 18122 (2005). 16330774 PMC1306793 source
The citation is attached to the statement that ACVR2B/Fc can induce rapid muscle growth. The source’s Results and Discussion report that its maximal effect was reached after two injections spaced one week apart. The 11% increase in lean body mass over 12 days is attributed to the citing paper’s Fig. 1D, not to this source. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interestingly, BMD in the humerus was not reduced in flight mice during this 22 d period, consistent with the differential effects of microgravity on the femur and humerus reported in rats (26) and humans (27).”
§ Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight > Results and Discussion
What the sources say
- Supportedcites [26] Keune J. A., Branscum A. J., Iwaniec U. T., Turner R. T., Effects of spaceflight on bone microarchitecture in the axial and appendicular skeleton in growing ovariectomized rats. Sci. Rep. 5, 18671 (2015). 26691062 PMC4687043 source
The citation is attached to the differential effects on femur and humerus in rats, not to the citing authors’ observation about mice during a 22-day period. The Results sections report lower femur BMD in flight rats but no significant effect of spaceflight on humerus BMD. (LLM, conf=0.93)
- Supportedcites [27] Stavnichuk M., Mikolajewicz N., Corlett T., Morris M., Komarova S. V., A systematic review and meta-analysis of bone loss in space travelers. NPJ Microgravity 6, 13 (2020). 32411816 PMC7200725 source
The citation is attached to the comparison with humans, not the citing paper’s finding in 22-day flight mice. In Results, under “Skeletal site-specific changes in bone density” (page unavailable), the source reports substantially greater bone loss in the lower limbs than in the upper-limb/thorax region of space travelers, supporting the stated differential effect. (LLM, conf=0.89)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The dual ability of ACVR2B/Fc to promote muscle growth and to increase bone density has suggested the possibility that this therapeutic strategy may be particularly useful to combat simultaneously comorbid muscle and bone loss, and indeed, this strategy has been shown to be effective in a mouse model of osteogenesis imperfecta, which is characterized by both muscle atrophy and bone fragility (21,”
§ Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight > Abstract
What the sources say
- Supportedcites [21] DiGirolamo D. J., Singhal V., Chang X., Lee S. J., Germain-Lee E. L., Administration of soluble activin receptor 2B increases bone and muscle mass in a mouse model of osteogenesis imperfecta. Bone Res. 3, 14042 (2015). 26161291 PMC4472144 source
The Results (page not supplied) report significant increases in trabecular bone measures and in several muscle weights after ACVR2B treatment of oim mice. The Introduction identifies this model as having deficits in muscle mass and function, while the Discussion describes low bone mass and fractures alongside muscle atrophy. The paper supports effectiveness for increasing bone and muscle mass; it does not establish improved fracture resistance. (LLM, conf=0.91)
- Partly supportedcites [22] Jeong Y.., Skeletal response to soluble activin receptor type IIB in mouse models of osteogenesis imperfecta. J. Bone Miner. Res. 33, 1760– 1772 (2018). 29813187 PMC6400483 sourceExperimental — accuracy not yet measured
The Results report increased skeletal muscle mass with sActRIIB-mFc treatment, and the Discussion reports improved trabecular bone architecture in both OI mouse models. The paper documents bone fragility, but the passages found do not establish that these models are characterized by muscle atrophy; it also reports no reduction in fracture occurrence. (LLM, conf=0.82)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Although advances in exercise devices and nutrition have significantly attenuated the bone mineral density losses observed during prolonged missions on vehicles like the International Space Station (ISS) (23, 24), future exploration missions to destinations like Mars will be significantly longer (∼3 y) and impose mass constraints that will not allow for the same, highly effective exercise”
§ Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight > Abstract
What the sources say
- Supportedcites [23] Smith S. M.., Benefits for bone from resistance exercise and nutrition in long-duration spaceflight: Evidence from biochemistry and densitometry. J. Bone Miner. Res. 27, 1896– 1906 (2012). 22549960 source
The Abstract states that improved nutrition and resistance exercise attenuated the BMD deficits previously observed after prolonged missions. The Discussion reports that ISS crewmembers with sufficient resistance exercise and adequate nutrition returned from 4-to-6-month missions with BMD seemingly unchanged from baseline in most skeletal regions. Page numbers are not provided in our copy. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [24] Sibonga J.., Resistive exercise in astronauts on prolonged spaceflights provides partial protection against spaceflight-induced bone loss. Bone 128, 112037 (2019). 31400472 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
44 more claims · 2 with their cited sources checked
Create a free account to see all 105 claims and every source verdict.
- It may state two separate claims as one. 36
- Probably not a substantial claim. 30
Citations
Cites
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 1×
“Because TRAIL and RANKL are known to regulate osteoclast differentiation and survival (33 – 35), these findings suggest that increased RANK (tumor necrosis factor receptor superfamily member 11a) signaling may be involved in the regulation of bone growth and remodeling induced by ACVR2B/Fc.…”
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Self-citationLDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development
Gong, Y., Slee, R. B., Fukai, N., Rawadi, G., Roman-Roman, S., Reginato, A. M., Wang, H., Cundy, T., Glorieux, F. H., Lev, D., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00571-2 · Cited by 2,235 · cited 1×
“Given that loss-of-function mutations in the Wnt receptor LRP5 results in low bone mass in both humans (47) and mice (48), the down-regulation of sFRP4, taken together with changes in levels of several Wnt inhibitors, suggests that altered Wnt signaling may play a role in bone loss resulting from exposure to micrograv…”
Double muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039
Self-citationAptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754 · cited 1×
“We carried out proteomic analysis of plasma using the SomaScan assay, which uses aptamers to measure relative levels of over 5,000 secreted proteins (31).”
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616 · cited 1×
“Signaling is initiated by binding of these ligands to the activin type II receptors, ACVR2 and ACVR2B (17).”
Self-citationSecreted antagonists of the Wnt signalling pathway
Kawano, Y., & Kypta, R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00623 · Cited by 1,584 · cited 2×
“Nevertheless, given that Dickkopfs are secreted proteins capable of antagonizing Wnt signaling by inhibiting the coreceptors LRP5 and LRP6 (43, 44), these findings suggest that increased Wnt signaling may also be involved in the increase in bone mass induced by ACVR2B/Fc.”
A deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399 · cited 1×
“Moreover, a heavily muscled boy was found to carry a mutation in a splice site in theMSTN gene, showing that MSTN plays a similar role in humans as well (12).”
Self-citationClop, A., Marcq, F., Takeda, H., Pirottin, D., Tordoir, X., Bibé, B., Bouix, J., Caiment, F., Elsen, J.-M., Eychenne, F., et al. (2006) · Nature Genetics · doi:10.1038/ng1810 · Cited by 1,260 · cited 1×
“The function of MSTN has been strongly conserved through evolution, as targeted or naturally occurring mutations in cattle (3–5), sheep (6), dogs (7), rabbits (8), rats (9), swine (10), and goats (11) have all been shown to lead to increased muscling.”
Cited by
Wu, M., Wu, S., Chen, W., & Li, Y.-P. (2024) · Cell Research · doi:10.1038/s41422-023-00918-9 · Cited by 445
Sarcopenia, osteoporosis and frailty
Gielen, E., Dupont, J., Dejaeger, M., & Laurent, M. R. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155638 · Cited by 258
Update on the effects of microgravity on the musculoskeletal system
Juhl, O. J., Buettmann, E. G., Friedman, M. A., DeNapoli, R. C., Hoppock, G. A., & Donahue, H. J. (2021) · npj Microgravity · doi:10.1038/s41526-021-00158-4 · Cited by 187
Pathophysiological mechanisms leading to muscle loss in chronic kidney disease
Wang, X. H., Mitch, W. E., & Price, S. R. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00498-0 · Cited by 170
The effects of microgravity on bone structure and function
Man, J., Graham, T., Squires-Donelly, G., & Laslett, A. L. (2022) · npj Microgravity · doi:10.1038/s41526-022-00194-8 · Cited by 183
“Mice N/A 33 • Spaceflight reduced BMD of whole body, and left and right femur by 8%, 11% and 8%, respectively compared to GC • Inhibition of myostatin/activin A signalling increases BMD in spaceflight mice comparable to untreated GC mice Lee et al.(41)”
Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction
Lee, S.-J. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148372 · Cited by 143
“On the one hand, many of these effects of blocking MSTN and activin A signaling may be beneficial for certain indications, such as aging as well as other conditions characterized by comorbid muscle and bone loss (47, 88, 94, 95).”
Self-citationMyostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
Rodgers, B. D., & Ward, C. W. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab030 · Cited by 111
Myostatin: a skeletal muscle chalone
Lee, S.-J. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012422-112116 · Cited by 84
Self-citationMay the Force Be with You (Or Not): The Immune System under Microgravity
ElGindi, M., Sapudom, J., Ibrahim, I. H., Al‐Sayegh, M., Chen, W., Garcia‐Sabaté, A., & Teo, J. C. M. (2021) · Cells · doi:10.3390/cells10081941 · Cited by 83
Sheng, R., Cao, M., Song, M., Wang, M., Zhang, Y., Shi, L., Xie, T., Li, Y., Wang, J., & Rui, Y. (2023) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2023.09.007 · Cited by 91
“Importantly, myostatin inhibition has shown great potential to improve both skeletal muscle and bone mass in osteosarcopenia [46,47].”
BackgroundSolagna, F., Tezze, C., Lindenmeyer, M. T., Lu, S. Y., Wu, G., Liu, S., Zhao, Y., Mitchell, R., Meyer, C., Omairi, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci135821 · Cited by 68
“We hypothesize that, while the initial source of the pro-cachectic and proinflammatory molecules is the kidney, other organs play a critical role in regulating the anabolic/ has already been used in preventing muscle wasting in different mouse models of glucocorticoid-induced atrophy (62), of microgravity (63), and of…”
BackgroundWetzlich, B., Nyakundi, B. B., & Yang, J. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05120-y · Cited by 78
Muscle-Bone Crosstalk in Chronic Obstructive Pulmonary Disease
Zhang, L., & Sun, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.724911 · Cited by 50
Pathophysiological mechanism of acute bone loss after fracture
Zheng, X.-Q., Huang, J., Lin, J., & Song, C. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.08.019 · Cited by 49
“addition, muscle atrophy occurs before bone changes [78,79], leading to a tilt in bone balance towards enhanced bone resorption.”
BackgroundMicrogravity and Musculoskeletal Health: What Strategies Should Be Used for a Great Challenge?
Bonanni, R., Cariati, I., Marini, M., Tarantino, U., & Tancredi, V. (2023) · Life · doi:10.3390/life13071423 · Cited by 60
A Pound of Flesh: What Cachexia Is and What It Is Not
Berardi, E., Madaro, L., Lozanoska‐Ochser, B., Adamo, S., Thorrez, L., Bouché, M., & Coletti, D. (2021) · Diagnostics · doi:10.3390/diagnostics11010116 · Cited by 47
“Targeting myostatin is known to prevent muscle wasting due to unloading during space flights [44], and proinflammatory cytokines play a role in wasting during reduced muscle activity, such as the recent COVID-19 quarantine [45].”
BackgroundCrosstalk between muscle and bone
Kaji, H. (2023) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-023-01472-5 · Cited by 44
“Moreover, the inhibition of myostatin/activin signaling protected against muscle wasting and bone loss induced by microgravity during spaceflight in mice [25].”
Barravecchia, I., Cesari, C. D., Forcato, M., Scebba, F., Pyankova, O. V., Bridger, J. M., Foster, H. A., Signore, G., Borghini, A., Andreassi, M. G., et al. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04025-z · Cited by 40
To infinity and beyond: Strategies for fabricating medicines in outer space
Seoane‐Viaño, I., Ong, J. J., Basit, A. W., & Goyanes, Á. (2022) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2022.100121 · Cited by 52
Pei, T., Zhu, D., Yang, S., Hu, R., Wang, F., Zhang, J., Yan, S., Ju, L., He, Z., Han, Z., et al. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17626 · Cited by 38
Deciphering Myostatin’s Regulatory, Metabolic, and Developmental Influence in Skeletal Diseases
Omosule, C. L., & Phillips, C. L. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.662908 · Cited by 34
Simulated microgravity accelerates aging of human skeletal muscle myoblasts at the single cell level
Takahashi, H., Nakamura, A., & Shimizu, T. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.09.037 · Cited by 32
Small tissue chips with big opportunities for space medicine
Mu, X., He, W., Rivera, V. A. M., Alba, R. A. D. D., Newman, D. J., & Zhang, Y. S. (2022) · Life Sciences in Space Research · doi:10.1016/j.lssr.2022.09.002 · Cited by 40
Furukawa, S., Chatani, M., Higashitani, A., Higashibata, A., Kawano, F., Nikawa, T., Numaga‐Tomita, T., Ogura, T., Sato, F., Sehara‐Fujisawa, A., et al. (2021) · npj Microgravity · doi:10.1038/s41526-021-00145-9 · Cited by 36
Advances in the research on myokine-driven regulation of bone metabolism
Shao, M., Wang, Q., Lv, Q., Zhang, Y., Gao, G., & Lu, S. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22547 · Cited by 36
“Myostatin also increased the expression of sclerostin SOST, Dickkopf-1 (DKK1), and RANKL, and decreased osteocyte-derived exosome Mir-218 by inhibiting muscle growth, thus inhibiting osteoblast differentiation [92,93].”
BackgroundAdvanced material technologies for space and terrestrial medicine
Chua, C. Y. X., Jiménez, M., Mozneb, M., Traverso, G., Lugo, R., Sharma, A., Svendsen, C. N., Wagner, W. R., Langer, R., & Grattoni, A. (2024) · Nature Reviews Materials · doi:10.1038/s41578-024-00691-0 · Cited by 36
“Leveraging these models, space investigation of other similar drugs such as ACVR2B/Fc could be impactful for protecting skeletal muscle and bone loss in terrestrial medicine 87 .”
Brightwell, C. R., Latham, C. M., Keeble, A. R., Thomas, N. T., Owen, A. M., Reeves, K. A., Long, D. E., Patrick, M. D., Gonzalez‐Velez, S., Abed, V., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi9134 · Cited by 29
“Genetic deletion strategies and soluble receptor/neutralizing antibodies have shown efficacy in attenuating musculoskeletal loss during cancer cachexia ( 18 , 19 ) and spaceflight ( 20 ), and several GDF8-targeting pharmaceutical products are currently in clinical development ( 21 – 24 ).”
BackgroundMcIntosh, M. C., Sexton, C. L., Godwin, J. S., Ruple, B. A., Michel, J. M., Plotkin, D. L., Ziegenfuss, T. N., Lopez, H. L., Smith, R. C., Dwaraka, V. B., et al. (2023) · Cells · doi:10.3390/cells12060898 · Cited by 32
“INHBA is a muscle growth inhibitor and encodes for activins which are a part of the TGF-β superfamily and have roles in the development regulation [45,46].”
BackgroundSkeletal muscle gene expression dysregulation in long-term spaceflights and aging is clock-dependent
Malhan, D., Yalçın, M., Schoenrock, B., Blottner, D., & Relógio, A. (2023) · npj Microgravity · doi:10.1038/s41526-023-00273-4 · Cited by 30
Mechanisms and Countermeasures for Muscle Atrophy in Microgravity
Liu, Y., Cao, X., Zhou, Q., Deng, C., Yang, Y., Huang, D., Luo, H., Zhang, S., Li, Y., Xu, J., et al. (2024) · Cells · doi:10.3390/cells13242120 · Cited by 33
Self-citationMicrogravity-induced alterations of mouse bones are compartment- and site-specific and vary with age
Coulombe, J. C., Sarazin, B. A., Mullen, Z., Ortega, A. M., Livingston, E. W., Bateman, T. A., Stodieck, L., Lynch, M. E., & Ferguson, V. L. (2021) · Bone · doi:10.1016/j.bone.2021.116021 · Cited by 24
Genchi, G. G., Degl’Innocenti, A., Martinelli, C., Battaglini, M., Pasquale, D. D., Prato, M., Marras, S., Pugliese, G., Drago, F., Mariani, A., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c14176 · Cited by 25
Emerging Treatment Options for Sarcopenia in Chronic Liver Disease
Kim, Y. (2021) · Life · doi:10.3390/life11030250 · Cited by 26
Cahill, T., Cope, H., Bass, J. J., Overbey, E. G., Gilbert, R., da Silveira, W. A., Paul, A. M., Mishra, T., Herranz, R., Reinsch, S. S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179470 · Cited by 23
Physical Activity, Exerkines, and Their Role in Cancer Cachexia
Bilski, J., Szlachcic, A., Ptak‐Belowska, A., & Brzozowski, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168011 · Cited by 25
Ha, P., Kwak, J. H., Zhang, Y., Shi, J., Tran, L., Liu, T. P., Pan, H.-C., Lee, S., Kim, J. K., Chen, E., et al. (2023) · npj Microgravity · doi:10.1038/s41526-023-00319-7 · Cited by 23
“In agreement with Lee et al. 67 , our data also showed that bone loss did not progress at a constant rate during space fl ight, with BMD loss slowing or even reversing after the fi rst 4.5 weeks after launch ( Fig.”
InfluentialSelf-citationDefinition and diagnosis of sarcopenia: Asia-Pacific perspectives
Huang, W.-F., Chen, Y., Chang, C., & Wu, C. (2025) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2025.05.004 · Cited by 26
“It is inferred that as-tronauts on long-term missions in space in the future will no longer suffer from muscle atrophy [88].”
Watson, C. J., Tang, W., Rojas, M. F., Fiedler, I. A. K., de Oca, E. M. M., Cronrath, A. R., Callies, K., Swearer, A. A., Ahmed, A. R., Sethuraman, V., et al. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010496 · Cited by 21
“Lastly, altered axial elongation has been observed in zebrafish mutants with primary defects in notochord (Ellis et al., 2013; Lim et al., 2017) and muscle activity (van der Meulen et al.”
BackgroundInfluentialImpacts of microgravity on amino acid metabolism during spaceflight
Dickerson, B. L., Sowinski, R. J., Kreider, R. B., & Wu, G. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702221139189 · Cited by 21
Ganse, B., Bosutti, A., Drey, M., & Degens, H. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112463 · Cited by 23
Liu, Y., Lehar, A., Rydzik, R., Chandok, H., Lee, Y., Youngstrom, D. W., George, J., Matzuk, M. M., Germain‐Lee, E. L., & Lee, S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111401118 · Cited by 21
“…the activities of certain TGF-β ligands using a decoy form of the ACVR2B/Fc receptor can lead to dramatic increases in muscle mass (20) and bone density (41 – 45), implying that the key ligands involved in regulating muscle and bone are likely to be ones capable of binding both FST and ACVR2B/Fc.”
InfluentialSelf-citationOmosule, C. L., Joseph, D., Weiler, B., Gremminger, V. L., Silvey, S., Jeong, Y., Rafique, A., Krueger, P., Kleiner, S., & Phillips, C. L. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4529 · Cited by 19
“Another monoclonal antimyostatin antibody (YN41) failed to improve bone microarchitecture in mice both on earth and in the microgravity space environment,((50)) although the reverse was true for an ACVR2B decoy receptor.((55)) Last, myostatin KO mice administered ActRIIBFc exhibited increased bone volume, suggesting t…”
BackgroundSchneider, D. J., Lynch, S. A., Gelinas, A. D., Ostroff, R. M., Rohloff, J. C., Williams, P., Janjić, N., & Drolet, D. W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821595-1.00007-5 · Cited by 20
Organ Crosstalk Contributes to Muscle Wasting in Chronic Kidney Disease
Wang, X. H., & Price, S. R. (2023) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151409 · Cited by 18
Sun, L., An, S., Zhang, Z., Zhou, Y., Yu, Y., Ma, Z., Fan, X., Tang, L., & Guo, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212112 · Cited by 22
Hanson, A. M., Young, M. H., Harrison, B. C., Zhou, X., Han, H. Q., Stodieck, L., & Ferguson, V. L. (2023) · npj Microgravity · doi:10.1038/s41526-022-00233-4 · Cited by 17
Optimization of Exercise Countermeasures to Spaceflight Using Blood Flow Restriction
Hughes, L., Hackney, K. J., & Patterson, S. D. (2022) · Aerospace Medicine and Human Performance · doi:10.3357/amhp.5855.2021 · Cited by 15
Zhang, J., Gao, Y., & Yan, J. (2024) · Metabolites · doi:10.3390/metabo14020088 · Cited by 19
Sadeghian, F., Divsalar, D. N., Fadil, R., Tavakolian, K., & Blaber, A. P. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.943630 · Cited by 16
“, 2019), pharmaceutical intervention (Lee et al., 2020), and artificial”
Benefits of Space Medicine Research for Healthcare on Earth
Shirah, B. H., Bukhari, H., Pandya, S., & Ezmeirlly, H. A. (2023) · Cureus · doi:10.7759/cureus.39174 · Cited by 23
“Countermeasures looking at mitigating these effects have included genetically augmenting mice to be more resistant to muscle mass loss and bone density loss, findings that potentially can offer insight into neuromuscular disease for Earth-based populations [12].”
BackgroundAdjuvant pharmacological strategies for the musculoskeletal system during long‐term space missions
Thomasius, F. E., Pesta, D. H., & Rittweger, J. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15877 · Cited by 17
“134 These and other studies fuelled a widespread effort to develop myostatin inhibitors for clinical use.”
Addressing the dark matter of gene therapy: technical and ethical barriers to clinical application
Kratzer, K., Getz, L. J., Peterlini, T., Masson, J., & Dellaire, G. (2021) · Human Genetics · doi:10.1007/s00439-021-02272-5 · Cited by 17
“For example, one could use gene editing to confer resistance to a deadly pathogen (The National Academy of Sciences 2020), or to prevent loss of muscle mass and bone density during spaceflight (Lee et al. 2020).”
BackgroundHurley-Novatny, A. C., Chang, D., Murakami, K., Wang, L., & Li, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1398050 · Cited by 21
“Notably, the effect of myostatin on bone loss are potentiated in the context of decreased mechanical loading (87, 89, 90).”
Cariati, I., Bonanni, R., Scimeca, M., Rinaldi, A. M., Marini, M., Tarantino, U., & Tancredi, V. (2022) · Life · doi:10.3390/life12050610 · Cited by 11
Musculoskeletal responses to spaceflight: mechanisms, countermeasures, and key gaps
Roberts, B. M., Deane, C. S., Szewczyk, N. J., Fajardo, V. A., Maden‐Wilkinson, T., & Bagley, J. R. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00649.2025 · Cited by 15
Metabolic stress in space: ROS-induced mutations in mice hint at a new path to cancer
Štolc, V., Karhánek, M., Freund, F., Griko, Y. V., Loftus, D. J., & Ohayon, M. M. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103398 · Cited by 9
Kaji, H. (2025) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2025.04.001 · Cited by 12
“Previous findings indicated that myostatin mediated osteopenia and bone destruction by affecting distant bones and joints in mice, and the inhibition of myostatin signaling attenuated microgravity-induced osteopenia in mice [24,25].”
Functional replacement of myostatin with GDF-11 in the germline of mice
Lee, S., Lehar, A., Rydzik, R., Youngstrom, D. W., Bhasin, S., Liu, Y., & Germain‐Lee, E. L. (2022) · Skeletal Muscle · doi:10.1186/s13395-022-00290-z · Cited by 8
Self-citationSun, P., Yang, J., Wang, B., Ma, H., Zhang, Y., Guo, J., Chen, X., Zhao, J., Sun, H., Yang, J., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91077-7 · Cited by 10
Kukes, V. G., Газданова, А. А., Furalyov, V. A., Маринин, В. Ф., Perkov, A., Lenkova, N., Solovyeva, S., & Ryazantseva, O. (2021) · Medical news of the North Caucasus · doi:10.14300/mnnc.2021.16079 · Cited by 10
microRNA, a Subtle Indicator of Human Cytomegalovirus against Host Immune Cells
Yu, M., Jin, Y., Zhang, S.-C., Xu, J., & Zhang, J. (2022) · Vaccines · doi:10.3390/vaccines10020144 · Cited by 11
Aging: A struggle for beneficial to overcome negative factors made by muscle and bone
Welc, S. S., Brotto, M., White, K. E., & Bonewald, L. F. (2025) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2025.112039 · Cited by 11
Emmert, M. E., Aggarwal, P., Shay‐Winkler, K., Lee, S., Goh, Q., & Cornwall, R. (2022) · eLife · doi:10.7554/elife.81121 · Cited by 9
Self-citationCoulombe, J. C., Jóhannesdóttir, F., Burkhart, K. A., Brummer, H., Allaire, B., & Bouxsein, M. (2023) · JBMR Plus · doi:10.1002/jbm4.10810 · Cited by 9
“(26) The association between paraspinal muscle density and vertebral trabecular bone density weakens in the immediate post-fl ight period, re fl ecting a high degree of interastronaut variability in the recovery of trabecular BMD.”
BackgroundActivins and Inhibins in Cardiovascular Pathophysiology
Tang, W., Gu, Z., Guo, J., Lin, M., Tao, H., Jia, D., & Jia, P. (2024) · Biomolecules · doi:10.3390/biom14111462 · Cited by 8
“Inhibiting activin production or activity promotes an increase in muscle volume and mass [114,115].”
Kishi, K., Goto, M., Tsuru, Y., & Hori, M. (2022) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.22-0097 · Cited by 7
“2023; 72(1): 68–76 A recent study showed that DXA can be used to noninvasively detect changes in muscle mass due to disuse atrophy [10].”
BackgroundOmosule, C. L., Joseph, D., Weiler, B., Gremminger, V. L., Silvey, S., Lafaver, B. N., Jeong, Y., Kleiner, S., & Phillips, C. L. (2023) · JBMR Plus · doi:10.1002/jbm4.10753 · Cited by 7
Kumar, H. S., Barnett, E. N., Fowlkes, J. L., Kalaitzoglou, E., & Annamalai, R. T. (2023) · JBMR Plus · doi:10.1002/jbm4.10804 · Cited by 11
“(52) Follistatin, an endogenous inhibitor of myostatin, is also shown to promote muscle growth.”
BackgroundThe critical impact of traumatic muscle loss on fracture healing: Basic science and clinical aspects
Rahmati, M., Haffner, M. R., Lee, M., Leach, J. K., & Saiz, A. M. (2023) · Journal of Orthopaedic Research® · doi:10.1002/jor.25746 · Cited by 11
“52,53 For example, a germline knockout of myostatin in mice leads to enlarged trabecular bone mass in vertebral bodies and a greater cortical area and periosteal circumference of the proximal humerus.”
BackgroundMusculoskeletal perturbations of deep space radiation: Assessment using a Gateway MRI
Jullienne, A., Malo, M. E., Shaw, K. A., Zheng, Y., Johnston, J. D., Kontulainen, S. A., Chilibeck, P. D., Dadachova, E., Obenaus, A., & Sarty, G. E. (2024) · Life Sciences in Space Research · doi:10.1016/j.lssr.2024.05.004 · Cited by 10
Cohen, O. E., Neuman, S., Natan, Y., Levi, A., Blum, Y. D., Amselem, S., Bavli, D., & Ben, Y. (2024) · Life Sciences in Space Research · doi:10.1016/j.lssr.2024.02.007 · Cited by 8
Long duration space missions: Challenges and prospects in sustaining humans in space
Kapoor, P., Yadav, R., Agrawal, N., Gaur, S., & Arora, R. (2025) · Life Sciences in Space Research · doi:10.1016/j.lssr.2025.05.001 · Cited by 9
Pharmacological Innovations in Space: Challenges and Future Perspectives
Aksoyalp, Z. Ş., Temel, A., & Karpuz, M. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03788-x · Cited by 9
“…of the mechanisms of muscle and bone loss in the microgravity environment will be of benefit to astro-nauts undertaking long-term missions in space, as well as to the prevention and treatment of unused muscle and bone loss in elderly, bedridden and wheelchair-bound individuals on Earth [35].”
Bone strength and composition in spacefaring rodents: systematic review and meta-analysis
Goldsmith, M., Crooks, S. D., Condon, S. F., Willie, B. M., & Komarova, S. V. (2022) · npj Microgravity · doi:10.1038/s41526-022-00195-7 · Cited by 8
Microgravity’s effects on miRNA-mRNA regulatory networks in a mouse model of segmental bone defects
Gautam, A., Chakraborty, N., Dimitrov, G. I., Hoke, A. V., Miller, S., Swift, K. A., Sowe, B., Conley, C., Kacena, M. A., & Hammamieh, R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0313768 · Cited by 6
TRPML1 ion channel promotes HepaRG cell differentiation under simulated microgravity conditions
Fan, H., Lü, D., Zheng, L., Li, H., Qi, Z., Sun, S., Guan, D., Long, M., Gao, M., & Liu, S. (2025) · npj Microgravity · doi:10.1038/s41526-025-00461-4 · Cited by 5
Muscle insulin-like growth factor-I modulates murine craniofacial bone growth
Kok, H. J., Crowder, C., Chee, L. K. M., Choi, H., Lin, N., & Barton, E. (2021) · European Cells and Materials · doi:10.22203/ecm.v042a06 · Cited by 4
A duty to enhance? Genetic engineering for the human Mars settlement
Kendal, E. S. (2024) · Bioethics News · doi:10.1007/s40592-024-00221-2 · Cited by 4
“Myostatin, also known as growth differentiation factor 8 (GDF8), is a protein that limits skeletal muscle mass and is encoded by the MSTN gene (Lee et al. 2020, p. 23942).”
InfluentialZhang, J., Wang, H., Yang, H., Kong, Y., Xu, S., Dang, K., Jiang, S., & Gao, Y. (2024) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/j.cbpa.2024.111716 · Cited by 7
Proposal for the binding mode of the 23-mer inhibitory peptide to myostatin
Asari, T., Ikeyama, H., Taguchi, A., Taniguchi, A., Hayashi, Y., & Takayama, K. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116181 · Cited by 4
Oribello, J. (2021) · San José State University ScholarWorks (San Jose State University) · doi:10.31979/etd.d4e7-x2g3 · Cited by 4
The Musculoskeletal System in Space
Clement, G. R. (2025) · Space technology library · doi:10.1007/978-1-0716-4422-5_5 · Cited by 3
Pérez‐Díaz, S., Baselet, B., Lovrić, A., Lundberg, T. R., Neefs, M., Daenen, L., Rullman, E., & Fernandez‐Gonzalo, R. (2025) · The Journal of Physiology · doi:10.1113/jp288987 · Cited by 5
“Despite evidence that physical activity (Furukawa et al., 2021) and certain pharmaceuticals (Lee et al., 2020) can help preserve astronauts’ muscle mass during missions, space-induced muscle atrophy remains a significant obstacle for future long-term spaceflight (Juhl et al., 2021).”
Gupta, A. E., Sharma, N., & Maender, C. C. (2021) · New Space · doi:10.1089/space.2021.0039 · Cited by 7
The Discovery of a Specific CKIP-1 Ligand for the Potential Treatment of Disuse Osteoporosis
Wei, Y., Wu, B., Liu, M., & Cui, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168870 · Cited by 4
“This irreversible bone loss caused by mechanical unloading poses a significant health challenge, particularly for astronauts on long-duration space missions [3], and has become one of the most significant limiting factors in long-term orbital spaceflight [4].”
BackgroundCaicedo, A., Castañeda, V., Díaz, J., Haro-Vinueza, A., Park, J., Kim, J. K., Overbey, E. G., Salinas, I., Nardocci, G., Camera, A., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2819258/v1 · Cited by 4
Hierholzer, J. D., Benson, H., Ewida, H. A., & Ahmed, M. S. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168172 · Cited by 4
Cadena, S. M., Bogdanovich, S., Khurana, T. S., Pullen, A. E., Pearsall, R. S., Curran, E., Faucette, R., Lane, J., Seehra, J. S., Lachey, J. L., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0342666 · Cited by 2
“In contrast, deficiency of either or both ligands in the form of genetic deletion [12–17] or pharmacological inhibition [17–22] results in increased muscle mass and rescue of muscle loss in models of muscle wasting.”
Gao, Y., Ge, L., Xiao, T., Du, F., Chen, J., Li, M., Chang, W., Yang, Y., & Zhang, J. V. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02976-z · Cited by 3
“Beyond reproduction, SMG affects multiple physiological systems, including skeletal muscle, bone, and the central nervous system [72–75].”
Genetic deletion of Kvβ2 (AKR6) causes loss of muscle function and increased inflammation in mice
Manickam, R., Virzi, J., Potti, A., Cheng, F., Russ, D. W., & Tipparaju, S. M. (2023) · Frontiers in Aging · doi:10.3389/fragi.2023.1175510 · Cited by 2
“In addition, we also noticed an increase in the Acvr1b, Hdac5, and Trim54/MuRF3 expression levels in the Kvβ2 KO mice suggesting possible activin receptor signaling, and neurogenic muscle atrophy of skeletal muscles in these mice leading to reduced muscle mass, grip strength, the contractile unit sarcomere length, myo…”
BackgroundBioinformatic analysis of the RNA expression patterns in microgravity-induced bone loss
Zhang, X., Xue, T., Hu, Z., Guo, X., Li, G., Wang, Y., Zhang, L., Xu, L., Cao, X., Zhang, S., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.985025 · Cited by 5
“In vivo, the blood and load-bearing bones are often used to elucidate the biological phenomenon and molecular mechanism underlying microgravity-induced bone loss (Caillot-Augusseau et al., 1998; Lee et al., 2020).”
BackgroundSuccess Stories: Incremental Progress and Scientific Breakthroughs in Life Science Research
Ruyters, G., Braun, M., & Stang, K. M. (2021) · SpringerBriefs in space life sciences · doi:10.1007/978-3-030-74022-1_3 · Cited by 2
Mahalakshmi, D., & Adeyeye, S. A. O. (2025) · Nutrition & Food Science · doi:10.1108/nfs-04-2025-0132 · Cited by 2
Trovão, N. S., Lucaci, A. G., Pradeep, N., Sethi, M., Bono, L. M., Singh, R. S., Clark, K. B., Zaksas, V., Burke, M., Caicedo, A., et al. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-32904-3.00009-1 · Cited by 3
Ouyang, X., Liu, J.-Y., Li, Z., Zhu, J., Li, W., He, R., Liu, S., Xue, Y., Huang, C., Zhang, J., et al. (2025) · World Journal of Traditional Chinese Medicine · doi:10.4103/wjtcm.wjtcm_21_25 · Cited by 1
Ravindran, S. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023335117 · Cited by 1
Biomechanical Stimulation of Muscles Influences Bone Phenotype by Modulating Myokine SecretionPreprint
Kumar, H. S., Barnett, E. N., Kalaitzoglou, E., Fowlkes, J. L., & Annamalai, R. T. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.05.510953 · Cited by 1
Omosule, C. L. (2021) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/90078
Wang, W., Zhong, Y., Zhou, Y., Yu, Y., Li, J., Kang, S., Ma, Z., Fan, X., Sun, L., & Tang, L. V. (2023) · The Journal of the Acoustical Society of America · doi:10.1121/10.0020835
Research Progress of Spaceflight Rodent Culture Devices and Experimental Techniques
Zhang, J. C., LÜ, Y., Zhang, T., & Fangwu, L. I. U. (2024) · Chinese Journal of Space Science · doi:10.11728/cjss2024.03.2023-0096
Metadata
- Authors
- Lee, S.-J., Lehar, A., Meir, J. U., Koch, C., Morgan, A., Warren, L. E., Rydzik, R., Youngstrom, D. W., Chandok, H., George, J., Gogain, J., Michaud, M., Stoklasek, T. A., Liu, Y., & Germain-Lee, E. L.
- Affiliations
- University of Connecticut (US)
- The Jackson Laboratory for Genomic Medicine (US)
- National Aeronautics and Space Administration (US)
- Center for the Advancement of Science in Space (US)
- SomaLogic (United States) (US)
- Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT 06030;
- Corresponding author
- Lee, Se-Jin
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2020-09-08
- Volume
- 117
- Issue
- 38
- Pages
- 23942-23951
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC7519220
- OpenAlex
- W3084261347
- Cited by
- 115
- References
- 54
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 17 · 2023: 21 · 2022: 19 · 2021: 27 · 2020: 3
- FWCI
- 10.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- Funders
- HHS | National Institutes of Health (R01AG052962, R01AR060636)
- Center for the Advancement of Science in Space (UA-2019-031)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Spaceflight effects on biology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Social Sciences › Political Science and International Relations › Space exploration and regulation
- Keywords
- myostatin, activin A, ACVR2B, microgravity, spaceflight, disuse atrophy, muscle atrophy, bone loss, skeletal muscle, bone mass, signaling pathways
- MeSH terms
- Animals, Bone Resorption, Female, Male, Mice, Inbred C57BL, Muscular Atrophy, Space Flight, Signal Transduction, Mice, Knockout, Muscle, Skeletal, Activins, Activin Receptors, Type II, Mice, Myostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.